Gilead Buying CV Therapeutics for $1.4B
Updated from 12:59 p.m. EDT
Gilead Sciences (GILD) is acquiring CV Therapeutics (CVTX) in a $1.4 billion cash deal that will boost Gilead's nascent cardiovascular drug franchise, the companies announced Thursday.
The acquisition values CV Therapeutics at $20 a share, or a 25% premium to the stock's closing price Wednesday. Gilead is swooping in with a higher offer for CV Therapeutics after Japanese drug maker Astellas sought to buy the company for $16 a share, an offer that was rebuffed multiple times by CV Therapeutics' board of directors.
Gilead is best known for its market-leading HIV drug franchise, but the company has recently branched out with drugs to treat pulmonary and cardiovascular disease. CV Therapeutics owns Ranexa, a drug to treat chronic angina, and Lexiscan, a cardiac stress agent.
Gilead is developing a new drug, darusentan, for persistent hypertension. Data from two phase III studies of darusentan are expected later this year. "The acquisition of CV Therapeutics represents a unique opportunity to complement and strengthen our growing cardiovascular portfolio," said Gilead chairman and CEO John Martin. Gilead says the acquisition of CV Therapeutics will be dilutive to earnings in 2009 and neutral to accretive in 2010. Gilead shares were gaining 0.9% to $43.43 in recent trading. Te Gilead-CV merger follows a slew of drug-firm deals in recent weeks, including Roche's purchase of Genentech (DNA) -- also announced Thursday -- Merck's (MRK) $41 billion merger with Schering-Plough (SGP), and Pfizer's (PFE) $68 billion acquisition of Wyeth (WYE)Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
